HUTCHMED (China) Limited
HCM evidence brief
What we can confirm
- Market Cap:
- $2.36B
What it means
What to watch
Prepared research question
What matters most for HCM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HCM
HUTCHMED (China) Limited is a Hong Kong- and Shanghai-headquartered biopharmaceutical company focused on discovering, developing, and commercializing oncology therapies, with a marketed portfolio including ELUNATE®, SULANDA®, and FRUZAQLA®, and a pipeline featuring novel Antibody-Targeted Therapy Conjugates (ATTCs).
Key risk: Modest cash reserves
Market Cap
$2.36B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 13 clinical trials for HUTCHMED (China) Limited.
HUTCHMED (China) Limited is a Hong Kong- and Shanghai-headquartered biopharmaceutical company focused on discovering, developing, and commercializing oncology therapies, with a marketed portfolio including ELUNATE®, SULANDA®, and FRUZAQLA®, and a pipeline featuring novel Antibody-Targeted Therapy Conjugates (ATTCs).
- Cash & equivalents of $71.3M and shareholders' equity of $1,237.9M as of 2025-12-31 [sec].
- China product sales recovery led by ELUNATE® and SULANDA® with over 40% growth each; FRUZAQLA® approved or launched in 41 countries ex-US [news · published 2026-07-30].
- Positive top-line results from the Phase III SAFFRON study of savolitinib (ORPATHYS®) in lung cancer [news · published 2026-08-17].
- Initiated global Phase I/IIa trial of ATTC candidate HMPL-A580 (PI3K/PIKK-EGFR) in solid tumors [news · published 2026-03-04].
- Entered a licensing agreement with GSK for a KRAS-EGFR cancer therapy worth up to US$1.295 billion, with $110M upfront [news · published 2026-09-03].
What works
- Commercial momentum: China product sales recovery with ELUNATE® and SULANDA® each growing over 40%, and FRUZAQLA® now approved or launched in 41 countries ex-US [news · published 2026-07-30].
- Late-stage pipeline validation: Positive top-line results from the global Phase III SAFFRON study of savolitinib in lung cancer [news · published 2026-08-17].
- Novel platform progress: Two ATTC candidates (HMPL-A251 and HMPL-A580) have entered global clinical development, representing a new source of drug candidates [news · published 2025-12-17][news · published 2026-03-04].
- Major partnership: A licensing agreement with GSK for a KRAS-EGFR therapy provides up to US$1.295 billion in potential milestones plus $110M upfront [news · published 2026-09-03].
What to weigh
- Cash position: Cash & equivalents of $71.3M as of 2025-12-31 is relatively modest for a company with multiple global trials and commercial operations [sec].
- Reliance on China market: A significant portion of product sales recovery is driven by China, exposing the company to regulatory and market risks in that region [news · published 2026-07-30].
- Early-stage pipeline risk: The ATTC platform candidates (HMPL-A251, HMPL-A580) are in Phase I/IIa, with no efficacy data yet, representing high technical and clinical risk [news · published 2025-12-17][news · published 2026-03-04].
- Competitive pressure: The KRAS-EGFR space is highly competitive, and the GSK deal's ultimate value depends on successful development and regulatory approval [news · published 2026-09-03].
From the filings
Quoted directly from source documents.
China product sales recovery with over 40% growth for ELUNATE and SULANDA
“China product sales recovery continues led by ELUNATE® and SULANDA® with over 40% growth each”
News · July 30, 2026
Risks & what to watch (4)›
Key risks
- Modest cash reserves — Cash & equivalents of $71.3M as of 2025-12-31 may limit ability to fund multiple global trials without additional financing [sec].
- China market concentration — Revenue recovery is heavily China-dependent, exposing the company to local regulatory and competitive shifts [news · published 2026-07-30].
- Early-stage ATTC pipeline — ATTC candidates HMPL-A251 and HMPL-A580 are in Phase I/IIa with no efficacy data, carrying high technical risk [news · published 2025-12-17][news · published 2026-03-04].
- Competitive KRAS-EGFR space — The GSK-partnered KRAS-EGFR therapy faces a crowded field; deal milestones depend on successful development and approval [news · published 2026-09-03].
What to watch
- Further data from the Phase III SAFFRON study of savolitinib (ORPATHYS®) in lung cancer [news · published 2026-08-17].
- Progress of ATTC candidates HMPL-A251 and HMPL-A580 through Phase I/IIa trials [news · published 2025-12-17][news · published 2026-03-04].
- Commercial uptake of ELUNATE® and SULANDA® in China and FRUZAQLA® ex-US [news · published 2026-07-30].
- Milestone payments and development updates from the GSK licensing agreement for the KRAS-EGFR therapy [news · published 2026-09-03].
Sources: Catalysts · News · Generated October 12, 2026 · How we verify sources →
Run HUTCHMED (China) Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HUTCHMED (China) Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
53
Total value held
$63.6M
| Holder | Shares | Value |
|---|---|---|
| schroder investment management group | 1,477,494 | $22.1M |
| allianz asset management gmbh | 837,475 | $12.5M |
| state street corp | 304,829 | $4.6M |
| aia group ltd | 291,229 | $4.4M |
| m&g plc | 255,468 | $3.8M |
| amundi | 232,246 | $3.5M |
| renaissance technologies llc | 132,062 | $2.0M |
| bnp paribas financial markets | 106,504 | $1.6M |
| crossmark global holdings, inc. | 84,963 | $1.3M |
| jane street group, llc | 76,514 | $1.1M |
Showing top 10 of 53 institutional holders of HUTCHMED (China) Limited. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.3%
- Days to cover
- 8.9
- Shares short
- 306,832
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HCM short interestGovernance
Frequently asked questions
What is the AI investment thesis for HUTCHMED (China) Limited?
HUTCHMED (China) Limited is a Hong Kong- and Shanghai-headquartered biopharmaceutical company focused on discovering, developing, and commercializing oncology therapies, with a marketed portfolio including ELUNATE®, SULANDA®, and FRUZAQLA®, and a pipeline featuring novel Antibody-Targeted Therapy Conjugates (ATTCs).
Who is the CEO of HUTCHMED (China) Limited?
Mr. Chig Fung Cheng BEc, CA is the chief executive officer of HUTCHMED (China) Limited (HCM).
Where is HUTCHMED (China) Limited headquartered?
HUTCHMED (China) Limited (HCM) is headquartered in Hong Kong, Hong Kong.
What therapeutic areas does HUTCHMED (China) Limited focus on?
HUTCHMED (China) Limited develops therapies across Oncology, Immunology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.